Ipsen S.A., a global biopharmaceutical group headquartered in France, has established itself as a leader in the healthcare industry since its founding in 1929. With a strong presence in Europe, North America, and Asia, Ipsen focuses on innovative treatments in oncology, neuroscience, and rare diseases.
The company is renowned for its core products, including Somatuline® and Cabometyx®, which are distinguished by their unique mechanisms of action and efficacy in treating complex conditions. Ipsen's commitment to research and development has led to significant milestones, including the expansion of its product portfolio and strategic partnerships that enhance its market position.
Recognised for its dedication to patient care and innovation, Ipsen continues to make strides in the biopharmaceutical sector, contributing to advancements that improve the quality of life for patients worldwide.
+30 vs industry average
Ipsen’s score of 68 is higher than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Ipsen?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2027
Reported emissions
Scope 3 accounts for ••• of total emissions.
Ipsen's reported carbon emissions
In 2024, Ipsen reported total greenhouse gas emissions of approximately 99,320,000 kg CO2e, comprising 9,932,000 kg CO2e from Scope 1, 5,790,000 kg CO2e from Scope 2, and 90,705,000 kg CO2e from Scope 3 emissions. The company has set ambitious climate commitments, aiming to reduce its absolute Scope 1 and 2 emissions by 50% by 2030, using 2019 as the baseline year. Additionally, Ipsen targets a 20% reduction in Scope 3 emissions within the same timeframe. Looking towards the long term, Ipsen is committed to achieving net-zero emissions across all scopes by 2045, with a target to reduce absolute emissions by at least 90% from the 2019 baseline. This commitment aligns with the Science Based Targets initiative (SBTi) and the Paris Agreement's goal to limit global warming to 1.5°C. Ipsen's emissions data is sourced directly from its own reporting, with no cascaded data from parent organizations. The company is actively working towards its sustainability goals within the pharmaceutical sector, demonstrating a strong commitment to environmental responsibility.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Ipsen’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Ipsen yet.
Scope 3 top emissions categories
10 of 15 categories disclosedSee all scope 3 categories
Already have an account? Sign in now
Climate initiatives
Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact Climate Champions initiative
RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisations
Ipsen
Frequently asked questions
Common questions about Ipsen’s sustainability data and climate commitments
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project